Breilh D, Allaouchiche B, Jaumain H, Boulétreau P, Chassard D, Malbec I, Ducint D, Saux M C
Clinical Pharmacokinetic Laboratory, Haut-Lévêque Hospital, University of Bordeaux II, Bordeaux, Lyon, France.
Antimicrob Agents Chemother. 1999 Oct;43(10):2409-11. doi: 10.1128/AAC.43.10.2409.
The objective of this study was to analyze the pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Six patients received 15 mg of isepamicin per kg of body weight. The mean isepamicin concentration peak in serum was 62.88 +/- 18.20 mg/liter 0.5 h after the infusion. The elimination half-life was 7. 91 +/- 0.83 h. The mean total body clearance was 1.75 +/- 0.28 liters/h, and dialysate outlet (DO) clearance was 2.76 +/- 0.59 liters/h. The mean volume of distribution was 19.83 +/- 2.95 liters. The elimination half-life, DO clearance, and volume of distribution were almost constant. In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma.
本研究的目的是分析异帕米星在持续静脉-静脉血液透析滤过过程中的药代动力学。6例患者接受了每千克体重15mg异帕米星的治疗。输注后0.5小时血清中异帕米星浓度峰值平均为62.88±18.20mg/升。消除半衰期为7.91±0.83小时。平均总体清除率为1.75±0.28升/小时，透析液出口（DO）清除率为2.76±0.59升/小时。平均分布容积为19.83±2.95升。消除半衰期、DO清除率和分布容积几乎恒定。在这组患者中，15mg/kg的初始剂量似乎足够，但给药间隔应通过监测血浆中残留的异帕米星浓度来确定。
